TaiRx Inc is a Taiwan-based company mainly engaged in the development and research of new drugs. The Company primarily focus on the research and development of cancer treatment drugs and sepsis adjuvant therapy drugs. The Company's main products include CVM-1118, Rexis, Zelnite, TRX-NOC, TRX-920, TRX-711, TRX-105 and others. CVM-1118 and Rexis are in clinical trials, and Zelnite drugs are sold to domestic medical institutions at all levels through distributors.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
21/08/26	NT$12.55	-2.33%	142,530
20/08/26	NT$12.85	-1.15%	13,258
19/08/26	NT$13.00	+0.78%	58,185
18/08/26	NT$12.90	-0.77%	46,268
17/08/26	NT$13.00	-0.38%	20,004

End-of-day quote Taipei Exchange

More quotes

End-of-day quote Taipei Exchange 21/08/2026			5-day change	1st Jan Change
12.55 ^TWD	-2.33%		-3.83%	-42.69%

08-11	TaiRx, Inc. Reports Earnings Results for the Half Year Ended June 30, 2026	CI
04-15	TaiRx, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI

Market Cap	1.41B 44.19M 37.85M 35.42M 32.42M 60.84M 4.23B 61.65M 418M 163M 2.12B 166M 162M 7.02B	P/E 2024	-20.5x	P/E 2025	-11x
Enterprise Value	1.08B 33.81M 28.96M 27.1M 24.81M 46.56M 3.24B 47.17M 320M 125M 1.63B 127M 124M 5.38B	EV / Sales 2024	286x	EV / Sales 2025	75.1x
Free-Float	100%	Yield 2024 *	-	Yield 2025	-

08-11	TaiRx, Inc. Reports Earnings Results for the Half Year Ended June 30, 2026	CI
04-15	TaiRx, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
22/09/25	TaiRx, Inc.(TPEX:6580) dropped from S&P Global BMI Index	CI
14/08/25	TaiRx, Inc. Reports Earnings Results for the Half Year Ended June 30, 2025	CI
11/04/25	TaiRx, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024	CI
23/09/24	TaiRx, Inc.(TPEX:6580) added to S&P Global BMI Index	CI
11/08/24	TaiRx, Inc. Reports Earnings Results for the Half Year Ended June 30, 2024	CI
11/04/24	TaiRx, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
09/08/23	TaiRx, Inc. Reports Earnings Results for the Half Year Ended June 30, 2023	CI
11/04/23	TaiRx, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	CI
10/08/22	TaiRx, Inc. Reports Earnings Results for the Half Year Ended June 30, 2022	CI
13/04/22	TaiRx, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	CI
09/08/21	Tairx, Inc. Reports Earnings Results for the Half Year Ended June 30, 2021	CI

1 day	-2.33%
1 week	-3.83%
Current month	-4.92%
1 month	-10.68%
3 months	-21.56%
6 months	-35.64%
Current year	-42.69%

TaiRx, Inc. Stock

Stocks

6580

TW0006580004

Biotechnology & Medical Research

Valuation: TaiRx, Inc.

Chart: TaiRx, Inc.

Latest news : TaiRx, Inc.

Press Releases: TaiRx, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: TaiRx, Inc.

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

1 week	12.3	13
1 month	12.3	13.85
Current year	11.95	23.45
1 year	11.95	31.8
3 years	11.95	44
5 years	11.95	89.5
10 years	11.95	89.5

Manager	Title	Age	Since
Yi Wen Chu IRC	Investor Relations Contact	-	-
Du Shieng Chien CEO	Chief Executive Officer	-	22/08/2011
Jackson Huang DFI	Director of Finance/CFO	-	05/10/2015

Director	Title	Age	Since
Du Shieng Chien CHM	Chairman	-	22/08/2011
Yi Wen Chu BRD	Director/Board Member	-	18/12/2013
Hsiu Hui Li BRD	Director/Board Member	-	22/08/2011

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
TAIRX, INC.	-2.33%	-3.83%	-51.64%	-51.54%	44.19M
LONZA GROUP AG	+1.09%	+5.26%	+4.52%	+23.38%	51.61B
REVOLUTION MEDICINES, INC.	-1.07%	+2.82%	+465.96%	+570.70%	44.89B
IQVIA HOLDINGS INC.	+1.47%	+9.79%	+35.92%	+20.21%	42.77B
BEONE MEDICINES AG	+1.44%	+7.77%	+19.38%	+84.65%	42.58B
CELLTRION, INC.	-0.93%	-4.33%	+16.18%	+55.82%	31.82B
MEDPACE HOLDINGS, INC.	+1.32%	+7.30%	+33.89%	+148.53%	17.33B
ASCENDIS PHARMA A/S	-0.60%	+1.93%	-	-	16.63B
EUROFINS SCIENTIFIC SE	+0.03%	+3.41%	+6.55%	+29.84%	14.76B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	+1.28%	+5.41%	+82.40%	+46.13%	14.09B
Average	+0.17%	+3.64%	+68.13%	+103.08%	27.65B
Weighted average by Cap.	+0.48%	+4.72%	+99.55%	+141.35%

	2024	2025
Net sales	8.22M 258K 221K 207K 189K 356K 24.7M 360K 2.45M 953K 12.41M 970K 948K 41.05M	27.88M 875K 750K 702K 642K 1.21M 83.76M 1.22M 8.29M 3.23M 42.07M 3.29M 3.22M 139M
Net income	-139M -4.36M -3.73M -3.49M -3.2M -6M -417M -6.08M -41.29M -16.1M -210M -16.37M -16.02M -693M	-221M -6.94M -5.95M -5.57M -5.09M -9.56M -664M -9.69M -65.76M -25.64M -334M -26.08M -25.51M -1.1B
Net Debt	-505M -15.85M -13.58M -12.71M -11.63M -21.83M -1.52B -22.12M -150M -58.55M -762M -59.53M -58.24M -2.52B	-330M -10.38M -8.89M -8.32M -7.61M -14.29M -993M -14.48M -98.25M -38.32M -499M -38.96M -38.11M -1.65B